Hepatitis Drugs Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-02-02　·　152 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 26,380 Mn
2033 年預估規模: USD 32,906 Mn
年複合成長率 CAGR: 3.2%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-02-02頁數 152報告編號 CMI2977

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Hepatitis Drugs Market, By Drug Class (Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals, and Thrombopoiesis Stimulating Agents), By Disease Type (Hepatitis B, Hepatitis C, and Others), By Route of Administration (Oral and injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

報告摘要

Hepatitis refers to an inflammatory condition of the liver. Viral infections of the liver classified as hepatitis include hepatitis A, B, C, D, and E. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are most likely to become ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women which increase maternal and fetal mortality and morbidity. Market Dynamics Increasing prevalence of hepatitis worldwide is expected to boost growth of the hepatitis drugs market. According to World Health Organization (WHO), in 2015, 257 million people were living with chronic hepatitis B infection, and in 2016, while 4.5 million (16.7%) of the people were diagnosed with hepatitis B . Hepatitis B can be prevented by safe and effective vaccines. Additionally, the WHO aims for eliminating viral hepatitis infections which include 90% reduction of new infections, 65% reduction in deaths resulting from viral hepatitis infections worldwide by 2030. However, factors such as longer development and approval time for hepatitis drugs is expected to hinder growth of the hepatitis drugs market during the forecast period. For instance, according to the National Center for Biotechnology Information 2017, the development of a new medicine for hepatitis from target identification through approval for marketing, takes 12 years or longer. Key features of the study • This report provides in-depth analysis of the hepatitis drugs market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2026 – 2033, considering 2025 as the base year • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players • It profiles key players in the global hepatitis drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies • Key players covered as a part of this study include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc. • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics • The global hepatitis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hepatitis drugs market, research and consulting firms, new entrants, and financial analysts Market Segmentation • Drug Class Insights (Revenue, USD Mn, 2026 - 2033) o Interferon Alphas o HIV NRTIs o Nucleotide Polymerase / NS5A Inhibitor Combinations o Hepatitis C Protease / NS5A Inhibitor Combinations o NS5A Inhibitors o Nucleotide Polymerase Inhibitors o Nucleoside Analogue Antivirals o Thrombopoiesis Stimulating Agents • Disease Type Insights (Revenue, USD Mn, 2026 - 2033) o Hepatitis B o Hepatitis C o Others • Route of Administration Insights (Revenue, USD Mn, 2026 - 2033) o Oral o Injection • Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033) o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • Regional Insights (Revenue, USD Mn, 2026 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Merck & Co. Inc. o Gilead Sciences Inc. o AbbVie Inc. o Bristol Myers Squibb Company o Hoffmann-La Roche Ltd. o LAURUS Labs, Zydus Cadila o Hetero Healthcare Limited o GlaxoSmithKline PLC. o Cipla Inc

目錄 Table of Contents

Table of Contents 1. Research Objective and Assumption o Research Objectives o Assumptions o Abbreviations 2. Market Overview o Report Description  Market Definition and Scope o Executive Summary  Market Snippet, By Drug Class  Market Snippet, By Disease Type  Market Snippet, By Route of Administration  Market Snippet, By Distribution Channel  Market Snippet, By Region o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  Market Opportunities o Impact Analysis o Market Trends o Key Developments o Regulatory Landscape o Epidemiology Analysis o Reimbursement Scenario o PEST Analysis 4. Global Hepatitis Drugs Market, By Drug Class, 2026-2033, (USD Mn) o Introduction  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Interferon Alphas  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o HIV NRTIs  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Nucleotide Polymerase / NS5A Inhibitor Combinations  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Hepatitis C Protease / NS5A Inhibitor Combinations  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o NS5A Inhibitors  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Nucleotide Polymerase Inhibitors  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Nucleoside Analogue Antivirals  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Thrombopoiesis Stimulating Agents  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends 5. Global Hepatitis Drugs Market, By Disease Type, 2026-2033, (USD Mn) o Introduction  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Hepatitis B  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Hepatitis C  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Others  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends 6. Global Hepatitis Drugs Market, By Route of Administration, 2026-2033, (USD Mn) o Introduction  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Oral  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Injection  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends 7. Global Hepatitis Drugs Market, By Distribution Channel, 2026-2033, (USD Mn) o Introduction  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Hospital Pharmacies  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Retail Pharmacies  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Online Pharmacies  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends 8. Global Hepatitis Drugs Market, By Region, 2026-2033, (USD Mn) o Introduction  Market Share Analysis, By Region, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, For Region, 2021 - 2033 o North America  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)  Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o U.S. o Canada o Europe  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)  Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o U.K. o Germany o Italy o France o Spain o Russia o Rest of Europe o Asia Pacific  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)  Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o China o Japan o India o ASEAN o Australia o South Korea o Rest of Asia Pacific o Latin America  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)  Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o Brazil o Mexico o Argentina o Rest of Latin America o Africa  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)  Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o North Africa o Central Africa o South Africa o Middle East  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)  Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o GCC Countries o Israel o Rest of Middle East 9. Competitive Landscape o Company Profiles  Merck & Co. Inc. o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Gilead Sciences Inc. o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  AbbVie Inc. o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Bristol Myers Squibb Company o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  F. Hoffmann-La Roche Ltd. o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  LAURUS Labs o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Zydus Cadila o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Hetero Healthcare Limited o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  GlaxoSmithKline PLC. o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Cipla Inc. o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies o Analyst Views 10. Section o References o Research Methodology o About Us and Sales Contact

提及公司

Merck & Co. Inc.Gilead Sciences Inc.AbbVie Inc.Bristol Myers Squibb CompanyHoffmann-La Roche Ltd.LAURUS Labs, Zydus CadilaHetero Healthcare LimitedGlaxoSmithKline PLC.Cipla Inc

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們